Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer
Authors:
- 5 July 2021
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 189 (3) , 747-757
Abstract
Background The aim of this study was to develop a machine learning (ML) based model to accurately predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) using pretreatment clinical and pathological characteristics of electronic medical record (EMR) data in breast cancer (BC). Methods The EMR data from patients diagnosed with early and locally advanced BC and who received NAC followed by curative surgery were reviewed. A total of 16 clinical and pathological characteristics was selected to develop ML model. We practiced six ML models using default settings for multivariate analysis with extracted variables. Results In total, 2065 patients were included in this analysis. Overall, 30.6% (n = 632) of patients achieved pCR. Among six ML models, the LightGBM had the highest area under the curve (AUC) for pCR prediction. After hyper-parameter tuning with Bayesian optimization, AUC was 0.810. Performance of pCR prediction models in different histology-based subtypes was compared. The AUC was highest in HR+HER2- subgroup and lowest in HR−/HER2- subgroup (HR+/HER2- 0.841, HR+/HER2+ 0.716, HR−/HER2 0.753, HR−/HER2- 0.653). Conclusions A ML based pCR prediction model using pre-treatment clinical and pathological characteristics provided useful information to predict pCR during NAC. This prediction model would help to determine treatment strategy in patients with BC planned NAC.Keywords
All Related Versions
This publication has 34 references indexed in Scilit:
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)Annals of Oncology, 2013
- Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancerBreast Cancer Research and Treatment, 2012
- Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancerJournal of Cancer Research and Clinical Oncology, 2011
- Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and SurvivalClinical Medicine & Research, 2009
- Support vector machines combined with feature selection for breast cancer diagnosisExpert Systems with Applications, 2009
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27Journal of Clinical Oncology, 2008
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast CancerJournal of Clinical Oncology, 2007
- Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant ChemotherapyJournal of Clinical Oncology, 2007
- Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28Journal of Clinical Oncology, 2005
- Influence of Neoadjuvant Chemotherapy on Serum Tumor Markers CA 15-3, MCA, CEA, TPS and TPA in Breast Cancer Patients with Operable DiseaseTumor Biology, 1997